Google
LH Stock Price & Analysis — Laboratory Corporation of America Holdings (Healthcare >> Diagnostics & Research)
LH FAQ
What is LH's P/E ratio?
Laboratory Corporation of America Holdings (LH) currently trades at a P/E ratio of 25.85.
What is LH's ROE?
Laboratory Corporation of America Holdings reports a Return on Equity (ROE) of 10.79%.
What is LH's dividend yield?
Laboratory Corporation of America Holdings offers a dividend yield of 0.00%.
What is LH's Quality Score?
Our AI rates LH's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LH?
Our AI Timing Score for LH is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LH belong to?
Laboratory Corporation of America Holdings is classified under the Healthcare >> Diagnostics & Research sector on the NYSE exchange
LH AI Analysis Summary
Our AI summary for LH: Laboratory Corporation of America Holdings (NYSE), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 25.85, ROE of 10.79%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 309.20
Price
-6.33
(-2.01%)
Day Change
|
|
|---|
LH, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1843
|
| Magic Formula Rank by ROE |
1843
|
| Magic Formula Rank by ROIC |
2097
|
| Price | 309.20 |
| PBV / Sector |
2.78 / -29.69
|
| Earning Per Share | 11.96 |
| PE / Sector |
25.85 / 48.18
|
| PEG or PE/Growth / Sector |
2.05 / 1.64
|
| Average 1M Daily Value |
199.41 M
GREAT
|
| Average 1W Daily Value |
305.65 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
58% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:07 |
| Symbol | LH |
| Name | LABORATORY CORPORATION OF AMERICA HOLDINGS |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NYSE |
| Listed Shares | 82.00 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 24,335.14 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 358 South Main Street, Burlington, NC, United States, 27215
Phone: 336 229 1127
Website: https://www.labcorp.com
Employees: 71,000
Description: Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
